The National Heart, Lung, and Blood Institute (NHLBI) intends to negotiate on a non-competitive basis with Boston University for a six-year supplement to integrate the Omni cohort into the Framingham Heart Study (FHS) contract. Authority: 41 U.S.C. 253(c)(1), as set forth in FAR 6.302-1. The Framingham Heart Study (FHS) began in 1948 as a prospective study of 5,209 men and women designed to identify factors related to coronary disease risk. As the study progressed, it was broadened to include other cardiovascular, lung and blood diseases, and to add ancillary investigations of diseases such as cancer, sleep apnea, and osteoporosis. In 1971, 5,124 offspring of the original cohort were added to permit examination of familial risk factors and disease patterns, and beginning in 2002 a third generation of 4,095 participants were recruited, examined, and are continuing to be followed-up for events. For several decades, Boston University has been the contractor for the FHS to examine and follow up the Framingham Cohort, Offspring, and Third Generation participants. The Omni cohort, consisting of minority residents of Framingham, MA, were initially recruited by FHS investigators of Boston University in 1994-1995 to complement FHS, reflecting the growing diversity of that community. The data-gathering process from the Omni cohort was carefully designed by the FHS investigators to be as similar to that for the FHS cohort as possible. The Omni cohort was recruited, examined, and followed by the same FHS staff that performed these tasks on the FHS cohort. Both FHS and Omni cohorts were also examined in the same facilities. Funding for the Omni cohort thus far has been provided through NIH grants awarded to Boston University; most of these grant awards have already ended or will be ending soon. Integrating the Omni cohort into the Boston University’s FHS contract would allow the Omni cohort participants to consistently receive the same surveillance and examination as the FHS participants. This would make the Framingham findings more reflective of the growing diversity of the community, as FHS investigators accomplish the main objectives laid out in the recent 7-year (FY 2008 – FY 2015) FHS contract renewal: 1) To identify genetic and environmental factors related to development of cardiovascular, lung and blood diseases; 2) To identify determinants of the evolution of risk factors, subclinical and clinical manifestations of cardiovascular, lung and blood diseases; and 3) To establish and make widely available a resource for genetic and non-genetic studies of disease risk using data from candidate genes, marker and single nucleotide polymorphism (SNP) scans, DNA, other biological specimens, and phenotype data from the participants. The period of performance for incorporating the Omni cohort into the FHS through a contract with Boston University will be June 1, 2009 through March 31, 2015. Omni participants will undergo an examination and will be followed regularly to ascertain the development of clinical events such as heart attack and stroke. For the first group of Omni cohort recruited in 1994-1998, an estimated 280 of them will receive the same physical examination as that planned for the FHS Offspring cohort participants. For the second Omni group recruited in 2003-2005, an estimated 270 of them will undergo the same physical examination currently conducted on the FHS Generation 3 participants. After the examination, the Omni cohort (both Omni Groups 1 and 2) will be contacted regularly and followed through the end of the contract period for the development of any cardiovascular diseases. The incumbent contractor has the unique capability to provide these required services to the NHLBI for continuation of this study. Inherent duplication of cost to the Government and unacceptable delays in completing this project make competition unfeasible. NOTE: PREPARATION COSTS - This notice does not commit the Government to pay for the preparation and submission of a capabilities statement. All responsible sources may submit a capability statement which shall be considered by the NHLBI. Interested respondents must submit, within 45 days of this announcement, written capability statements demonstrating their ability to perform this research effort on the Omni study participants. Responses providing insufficient information for evaluation will not be considered. This is not a request for proposals.